BioDelivery Sciences International, Inc. (NASDAQ:BDSI) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 1,433,007 shares, an increase of 32.5% from the November 15th total of 1,081,713 shares. Approximately 2.8% of the shares of the stock are short sold. Based on an average trading volume of 561,756 shares, the short-interest ratio is presently 2.6 days.

BioDelivery Sciences International (NASDAQ BDSI) opened at $2.80 on Wednesday. The company has a quick ratio of 1.07, a current ratio of 1.28 and a debt-to-equity ratio of 1.89. BioDelivery Sciences International has a 1 year low of $1.55 and a 1 year high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The business had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. During the same period last year, the company earned ($0.30) EPS. BioDelivery Sciences International’s revenue for the quarter was up 215.1% compared to the same quarter last year. analysts predict that BioDelivery Sciences International will post 0.16 earnings per share for the current year.

Several equities analysts have recently commented on BDSI shares. Roth Capital set a $5.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 13th. Cantor Fitzgerald set a $5.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Thursday, October 12th. HC Wainwright started coverage on BioDelivery Sciences International in a research report on Sunday, September 10th. They set a “buy” rating and a $5.00 price objective on the stock. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Piper Jaffray Companies set a $4.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Sunday, October 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $4.29.

In other BioDelivery Sciences International news, insider Mark A. Sirgo sold 201,373 shares of the firm’s stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $2.84, for a total value of $571,899.32. Following the sale, the insider now owns 1,509,262 shares of the company’s stock, valued at approximately $4,286,304.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.73% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Krilogy Financial LLC grew its position in BioDelivery Sciences International by 28.8% during the 3rd quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after acquiring an additional 30,000 shares during the last quarter. Royce & Associates LP bought a new position in BioDelivery Sciences International during the 3rd quarter worth approximately $3,814,000. Stonepine Capital Management LLC grew its position in BioDelivery Sciences International by 11.2% during the 3rd quarter. Stonepine Capital Management LLC now owns 3,867,400 shares of the specialty pharmaceutical company’s stock worth $11,409,000 after acquiring an additional 389,727 shares during the last quarter. Wells Fargo & Company MN grew its position in BioDelivery Sciences International by 138.2% during the 3rd quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 20,599 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in BioDelivery Sciences International during the 3rd quarter worth approximately $116,000. Institutional investors and hedge funds own 44.08% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/12/19/short-interest-in-biodelivery-sciences-international-inc-bdsi-expands-by-32-5.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.